Obesity drugs with a new warning. FDA decision

The FDA warns that GLP-1 medications may increase the risk of a rare eye condition called NAION, which can lead to sudden vision loss. This applies to all GLP-1 drugs, including older diabetes medications. A study indicated that diabetes patients on semaglutide had a fourfold higher risk of developing NAION. The exact mechanism behind this increased risk remains unclear, but it may relate to underlying health issues in patients. Despite the risks, experts emphasize the benefits of GLP-1 drugs for managing diabetes and obesity. Patients are advised to report any vision changes immediately to their doctors.